The top 10 projected best-selling medications in 2026, including GLP-1 drugs and AbbVie's Skyrizi, have expected global sales reaching up to $31 billiion.

induction therapy to eliminate the need for in-clinic IV infusions required for Skyrizi and Omvoh. The ASTRO trial, whose full results will be revealed at ECCO 2025, has already demonstrated ...

and AbbVie’s Skyrizi (risankizumab). Both drugs brought in $132m and $11bn respectively, however, both currently rely on an initial intravenous infusion. J&J’s competition does have the edge ...

AbbVie reported better-than-expected fourth-quarter earnings. Strong demand for the company's Skyrizi and Rinvoq autoimmune therapeutics has helped offset the decline in Humira sales since losing ...

UCB’s Bimzelx is firmly on physicians’ radars, with Spherix Global Insights finding that awareness of the drug was tracking ahead of AbbVie’s Rinvoq and Skyrizi three months into its ...

(RTTNews) - AbbVie Inc. (ABBV) Tuesday said that its Skyrizi approved for the treatment of adults with moderately to severely active ulcerative colitis is now available in Canada. Ulcerative ...

The new formulation of the alpha-4 beta-7 integrin antagonist is intended for use after the current intravenous formulation ... including drugs like AbbVie’s Skyrizi (risankizumab) and Johnson ...

While earnings of $2.16 per share declined around 22% year over year, sales rose 6.1% on an operational basis, mainly driven by robust sales of its immunology medicines, Skyrizi and Rinvoq. While ...